Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Farhad Ghorbani | Shiraz University of Medical Sciences ,Shiraz,Iran | Iran

Dr. Farhad Ghorbani is an esteemed Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. With over two decades of clinical and academic experience, he has significantly contributed to the fields of oral pathology, trauma, and surgical interventions. A graduate of Kerman University of Medical Sciences, Dr. Ghorbani later specialized further at Shiraz University. His dedication to advancing clinical knowledge is reflected in over a dozen high-impact peer-reviewed publications, focusing on craniofacial abnormalities, surgical outcomes, and rare oral diseases. He is an active researcher with a Scopus Author ID and ORCID, consistently contributing to scientific journals like BMC Oral Health, Scientific Reports, and Maxillofacial Plastic and Reconstructive Surgery. His multidisciplinary collaborations have led to enhanced diagnostic techniques and patient outcomes. Dr. Ghorbani is recognized for both his innovative research and his commitment to medical education.

Publication Profile: 

Orcid

Google Scholar

Education:

Dr. Ghorbani began his medical journey at Kerman University of Medical Sciences, earning his professional doctorate in dentistry (1992–1998). Following years of clinical practice, he advanced his academic and surgical expertise by joining Shiraz University of Medical Sciences in 2013, where he underwent specialized training in Oral and Maxillofacial Surgery and served as an Assistant Professor during his educational tenure (2013–2018). His academic training focused on maxillofacial pathology, surgical techniques, and interdisciplinary diagnostics. The combination of strong foundational medical education and advanced surgical specialization has equipped him with both the theoretical depth and clinical acumen to lead impactful research. His training underlines a commitment to academic excellence and lifelong learning, which is further reflected in his scholarly contributions. Dr. Ghorbani’s educational background bridges foundational dental sciences with advanced surgical innovation.

Experience:

Since December 2018, Dr. Farhad Ghorbani has held the position of Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. His career blends clinical practice, research, and teaching. Over the years, he has led numerous studies exploring craniofacial morphology, surgical outcomes, dental trauma, and maxillofacial pathologies. He mentors postgraduate students and collaborates with interdisciplinary teams, enhancing diagnostic accuracy and surgical care. His work in both rural and urban settings has exposed him to a wide spectrum of maxillofacial cases, enriching his clinical insights. He actively contributes to improving surgical protocols and patient care standards. Dr. Ghorbani’s experience also includes academic publishing, peer reviews, and participation in scientific forums. He is recognized for his analytical approach and evidence-based practice. His long-standing affiliation with reputed institutions and research groups underscores his strong leadership in oral surgery and academic scholarship.

Research Focus:

Dr. Ghorbani’s primary research interests lie in oral pathology, craniofacial surgery, dentoalveolar trauma, and radiological diagnostics. His work often combines clinical case reports with retrospective analysis, offering insights into rare presentations such as parathyroid carcinoma-linked jaw tumors, and developmental anomalies like concha bullosa. A hallmark of his research is his ability to identify atypical symptoms and connect them with broader systemic conditions, ensuring early diagnosis and management. He has conducted fractal analysis studies to evaluate bone quality, and he explores patient-centered outcomes, such as satisfaction post-rhinoplasty and the psychological impacts of facial surgery. Additionally, his research evaluates the intersection of dental surgery with systemic health—evident in studies related to auditory changes post-orthognathic surgery or the implications of COVID-19 on dental care. Through evidence-based methods and innovative case analyses, Dr. Ghorbani has positioned himself as a thought leader in interdisciplinary oral and maxillofacial research.

Publications Top Notes:

  1. Brown tumors of both jaws as the initial manifestation of parathyroid carcinoma (BMC Oral Health, 2025)

  2. Distribution and laterality of concha bullosa across cranial skeletal types (Maxillofacial Plastic Surg, 2025)

  3. Calcifying Odontogenic Cyst in Posterior Maxilla: A Case Report (Journal of Dentistry Shiraz, 2025)

  4. Central giant cell granuloma mimicking fibro-osseous lesion and hemangioma (J Med Case Reports, 2024)

  5. Fractal CT analysis of mandibular condyles in class III malocclusion (Scientific Reports, 2023)

  6. Patient dissatisfaction following rhinoplasty: A 10-year Iranian study (Maxillofacial Plastic Surg, 2023)

  7. Correlation between impacted third molar and blood group (Int J of Dentistry, 2021)

  8. Effects of orthognathic surgery on auditory function (Maxillofacial Plastic Surg, 2021)

  9. Evaluation of alveolar fractures in trauma patients in Iran (BMC Oral Health, 2021)

  10. Anxiety in patients undergoing mandibular third molar extraction (J Oral Research & Review, 2020)

Conclusion:

In summary, Dr. Farhad Ghorbani embodies the qualities of a deeply committed, analytically skilled, and academically active oral and maxillofacial surgeon. His research is directly informed by his clinical experience, allowing him to bridge theory and practice effectively. His contributions have enriched the literature on oral pathology, surgical complications, facial aesthetics, and patient psychology following treatment interventions. While there are opportunities to expand the scope and scale of his work through more robust methodologies and international collaboration, his existing portfolio already reflects a high standard of academic and clinical integration. Given his track record, ongoing research productivity, and evident commitment to innovation and education, Dr. Ghorbani is a strong and deserving candidate for the Best Researcher Award. With continued growth in research leadership and expanded global outreach, he is poised to make an even greater impact in the years ahead.

Mogana Das Murtey | Cancer Cell Biology | Best Researcher Award

Dr. Mogana Das Murtey | Cancer Cell Biology | Best Researcher Award

Dr. Mogana Das Murtey , Universiti Sains Malaysia , Malaysia

Dr. Mogana Das Murtey is a Senior University Lecturer at Universiti Sains Malaysia (USM), with extensive expertise in cancer biology, microscopy, and toxicology. She holds a Ph.D. in Molecular and Cellular Biology from USM, where she also earned her Master of Science in Pathology. With more than a decade of teaching experience, Dr. Murtey has contributed significantly to scientific research and education. Her research has focused on cancer prevention, particularly through natural products, and includes groundbreaking studies in toxicology and microscopy techniques. She is a committed mentor and has published extensively in international journals, with multiple awards for her innovative contributions to science. She is an active member of various professional organizations, including the Royal Microscopy Society (UK), and regularly serves as a reviewer for leading journals. Dr. Murtey is dedicated to advancing scientific knowledge in the fields of cancer research and microscopy.

Publication Profile:

Google Scholar

Strengths for the Award:

  1. Extensive Research Experience:

    • Dr. Murtey has significant experience in cancer biology, microscopy, and toxicology, with notable contributions to these fields. His research is regularly published in peer-reviewed journals, such as the Journal of Oncology, Asian Pacific Journal of Cancer Prevention, and Oxidative Medicine and Cellular Longevity.
    • He has contributed as both first and corresponding author in reputable journals, demonstrating leadership and a high level of responsibility in his research endeavors.
    • His work spans multiple cancer types, including breast cancer, cervical cancer, and salivary gland carcinoma, showing both depth and breadth in his research areas.
  2. Innovative Approaches in Cancer Chemoprevention:

    • Dr. Murtey has worked on several groundbreaking studies, particularly in the area of natural product chemoprevention, such as using paddy husk and other plant-based materials to fight cancer. His research could potentially impact public health by offering new, cost-effective cancer treatments or prevention strategies.
    • He has intellectual property (copyright) for novel techniques, including immunogold techniques for scanning electron microscopy, showcasing his contribution to advancing scientific methods.
  3. Teaching and Mentorship:

    • As a Senior University Lecturer, Dr. Murtey has a strong commitment to teaching, having taught a variety of courses in oral biology, histology, and medical sciences, mentoring the next generation of scientists.
    • He has been an academic leader, holding positions like course coordinator and serving on multiple committees within his institution, further highlighting his administrative and leadership qualities.
  4. Recognition and Awards:

    • He has been recognized for his innovative research, including winning gold medals for his work on prostate disease chemoprevention and other health-related innovations.
    • His consistent recognition in prestigious events and competitions reflects the high regard in which his work is held by peers and experts in the field.
  5. Research Grants:

    • Dr. Murtey has secured significant research funding, including bridging and short-term grants from Universiti Sains Malaysia, for projects that involve cutting-edge research on cancer prevention and treatment.
  6. International Collaboration and Publication:

    • His research has international reach, evidenced by publications in global journals and his participation in conferences and symposiums. Furthermore, he serves as a reviewer for multiple respected journals, adding to his credibility and influence within the academic community.

Areas for Improvement:

  1. Increased Focus on Collaborative Research:

    • While Dr. Murtey has a strong individual publication record, more large-scale collaborative projects or multi-disciplinary research could further enhance his impact, particularly in advancing the translation of his findings into clinical or public health applications.
  2. Broader Outreach and Impact:

    • His work, although recognized in academia, could benefit from a stronger outreach strategy aimed at translating his findings into broader societal benefits. This could include partnerships with industry, public health organizations, or policymakers to implement his research at a larger scale.
  3. Grant Diversification:

    • Expanding beyond institutional and national grants to attract more international or industry-backed funding could further solidify his position as a global leader in his field. Additionally, incorporating more collaborative grants with researchers across different fields or industries may provide more extensive funding opportunities.

Education:

Dr. Mogana Das Murtey pursued her academic journey at Universiti Sains Malaysia (USM), where she completed her Ph.D. in Molecular and Cellular Biology (2013-2018). Her research focused on cancer biology and cellular mechanisms, making significant contributions to the understanding of cancer prevention. Prior to her doctoral studies, Dr. Murtey earned a Master of Science in Pathology from USM (2009-2013), where she specialized in understanding diseases at the cellular and molecular levels. She also holds a Bachelor’s degree in Biomedicine (Honours) from Management and Science University (2005-2009), where she first developed her passion for biomedical sciences. Dr. Murtey’s educational background has provided her with a solid foundation in both the theoretical and practical aspects of biomedical research, and she has continually applied her knowledge through teaching, mentoring, and extensive research in her field.

Experience:

Dr. Mogana Das Murtey has over a decade of teaching and research experience in the field of molecular and cellular biology. She is a Senior University Lecturer at Universiti Sains Malaysia (USM), where she has been since 2019. Throughout her career, Dr. Murtey has taught a variety of pathology and oncology-related courses, including Oral Biology, Oral Histology, and Basic Medical Sciences. Her role also includes supervising research projects at both the undergraduate and graduate levels. Before her current position, Dr. Murtey taught part-time at several institutions, including Sultan Abdul Halim Muadzam Shah International Islamic University and Allianze University College of Medical Sciences. In addition to her academic roles, she has been an active researcher, publishing numerous articles in peer-reviewed journals and contributing to groundbreaking work in cancer research and toxicology. Her work has led to several prestigious research grants and collaborations both locally and internationally.

Awards and Honors:

Dr. Mogana Das Murtey has been recognized with multiple awards for her innovative contributions to science. She won the Art Science Competition 2023 organized by the School of Medical Sciences, USM, for her outstanding scientific innovation. She also received a Gold Medal for her research on the chemopreventive agent “Pamentm: New Chemopreventive Agent for Prostate Disease” at the SIRIM Invention, Innovation & Technology Expo 2022. Additionally, Dr. Murtey received the Gold Medal at the Virtual International Research and Innovation Symposium and Exhibition (RISE 2021) at Universiti Tun Hussein Onn Malaysia. Her work has been acknowledged for its impact on advancing cancer research, particularly in cancer prevention through natural products. These awards reflect her commitment to excellence in research and innovation. Dr. Murtey’s achievements underscore her leadership in the academic and research communities.

Research Focus:

Dr. Mogana Das Murtey’s research primarily focuses on cancer biology, toxicology, and microscopy, with a special emphasis on the chemopreventive potential of natural products. Her research aims to identify new ways to prevent and treat various types of cancer, particularly through the use of natural compounds. She has been involved in groundbreaking studies on the pharmacological potentials of paddy waste products, such as husk and straw, in preventing cancer. Dr. Murtey’s work also includes exploring the role of microscopy techniques, such as scanning electron microscopy and immunogold labeling, to study cellular structures in detail. She has also contributed significantly to the understanding of toxicological effects and how certain substances impact cellular function. Her research has been widely published, and she continues to lead projects that explore the intersection of molecular biology, cancer prevention, and environmental science.

Publication Top Notes:

  1. Chemopreventive Potential of Paddy Waste: A Promising Approach Against Benign Prostate Hyperplasia in Spontaneously Hypertensive Rats 🌾💡
  2. Chemoprevention of Natural Products Against Oral Cancer: A Comprehensive Review 🍃🦷
  3. Negative Staining: Forgotten Technique in Microbiology 🧫🔬
  4. Chemopreventive Activity of Two Varieties of Freeze-Dried Coconut Water Against Cervical Cancer Cells, HeLa 🥥🧪
  5. Evaluation of Effect of Honey Sugars Analogue Therapy Against Breast Cancer Induced by 1-Methyl-1-Nitrosourea in In Vivo Breast Cancer Model 🍯🎗️
  6. Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial 💊🔬
  7. Development of Myocardial Infarction in Rat Model of Diet-Induced Hypercholesterolemia 🐀💔
  8. Gliclazide in Binary and Ternary Systems Improves Physicochemical Properties, Bioactivity, and Antioxidant Activity 💊🌿
  9. Life Science Sample Preparations for Scanning Electron Microscopy 🔬💡
  10. The Phytochemical Analysis and Pharmacological Potentials of Husk and Straw as Paddy Waste Products 🌾🍃

Conclusion:

Dr. Mogana Das Murtey is an exemplary candidate for the “Best Researcher Award” due to his profound contributions to cancer biology, particularly in the areas of chemoprevention and innovative microscopy techniques. His extensive publication record, innovative research methodologies, intellectual property contributions, and recognition from peers and institutions provide compelling evidence of his excellence. While there are areas where increased collaboration and broader outreach could further enhance his career, his consistent track record of success and leadership in both research and teaching positions him as a strong contender for the award.

Huifeng Hao | Tumor pharmacology | Best Researcher Award

Dr. Huifeng Hao | Tumor pharmacology | Best Researcher Award

Dr. Huifeng Hao , Peking University Cancer Hospital , China

Dr. Huifeng Hao is an Assistant Investigator at Peking University Cancer Hospital, specializing in the integration of Chinese and Western medicine. He holds a Ph.D. from Peking University Health Science Center, where he explored Chinese-Western medical integration. His research journey began with a Bachelor’s in Clinical Medicine from Hebei Medical University. Dr. Hao has accumulated valuable postdoctoral experience at Peking Union Medical College (PUMC) in Vascular Pharmacology. His work has greatly contributed to the understanding of cancer progression, focusing on the interactions between cancer cells and vascular endothelial cells and the therapeutic effects of Traditional Chinese Medicine. With over a decade of expertise, Dr. Hao has published extensively in renowned journals, addressing critical topics in cancer research, endothelial cell function, and vascular health.

Publication Profile:

Orcid

Strengths for the Award:

  1. Extensive Educational and Research Background: Dr. Huifeng Hao has a comprehensive and solid academic foundation. With a Bachelor’s degree in Clinical Medicine from Hebei Medical University and a Ph.D. in the Integration of Chinese and Western Medicine from Peking University Health Science Center, his educational background is robust. Moreover, his postdoctoral research in Vascular Pharmacology at Peking Union Medical College significantly bolsters his expertise, particularly in vascular biology and its implications in cancer progression.

  2. Groundbreaking Research Areas: Dr. Hao’s research primarily focuses on the complex interactions between cancer cells and vascular endothelial cells, along with exploring how Traditional Chinese Medicine (TCM) can influence cancer progression. This intersection of modern pharmacology and traditional medicine offers a unique and innovative approach to cancer therapy. His studies on cancer metastasis, endothelial cell signaling, and the use of TCM as a potential therapeutic strategy for cancer represent cutting-edge work.

  3. Impressive Publication Record: Dr. Hao has co-authored numerous high-impact publications in leading journals, such as Phytomedicine, Frontiers in Pharmacology, Journal of Ethnopharmacology, and Journal of Cellular and Molecular Medicine. His work spans across critical cancer pathways, pharmacological interventions, and the exploration of novel therapeutic agents like Marsdenia Tenacissima and Berberine in combating metastasis and endothelial dysfunction.

    • His 2022 papers on the modified Bu-Fei decoction’s effects on lung metastasis and the role of CUEDC2 in promoting breast cancer progression are particularly notable for their novel findings and potential clinical applications.
  4. Collaborative and Multi-Disciplinary Research: Dr. Hao’s ability to collaborate with a wide array of experts and researchers in diverse fields demonstrates his interdisciplinary approach to solving complex scientific questions. This collaboration enhances the relevance and applicability of his work in various research areas, particularly in cancer biology, pharmacology, and integrative medicine.

  5. Pioneering Work on TCM in Cancer Therapy: Dr. Hao’s research on the role of Traditional Chinese Medicine (TCM) in cancer therapy is especially noteworthy. His studies examining how TCM influences tumor microenvironments and endothelial cell interactions provide critical insights into how integrative medicine might be leveraged to treat cancer in combination with conventional therapies. This pioneering research has the potential to redefine cancer treatments and offer patients holistic therapeutic options.

  6. Strong Impact on Cancer Research: His work on vascular pharmacology, tumor angiogenesis, and metastasis in lung cancer, particularly through the modulation of transforming growth factor beta receptors and nitric oxide signaling, has significant implications for the development of new cancer therapies. His publications are contributing valuable knowledge toward better understanding cancer progression and discovering more effective treatments.

Areas for Improvement:

  1. Broader Research Scope in Clinical Settings: While Dr. Hao’s research has focused heavily on preclinical studies, including animal models and cellular assays, expanding his research into clinical trials or human-based studies would provide essential validation for his findings. Involving clinical datasets and patient-centered research could strengthen the real-world applicability of his work.

  2. Increase in Independent Research Funding: While Dr. Hao has contributed significantly to various collaborative projects, securing independent research grants would allow him more freedom to explore his unique research hypotheses in greater depth and broaden the scope of his investigations.

  3. Expansion of International Collaborations: While Dr. Hao’s collaborations are impressive, further expanding his international network could provide additional insights and allow him to take his research to the global forefront. Partnerships with leading international cancer research institutions could also amplify the impact of his work.

Education:

  • 2004.09-2009.06: Hebei Medical University (Bachelor Degree in Clinical Medicine)
  • 2009.09-2014.06: Peking University Health Science Center (Ph.D. in Integration of Chinese and Western Medicine)
  • 2014.09-2018.08: Peking Union Medical College (Postdoctoral Training in Vascular Pharmacology)

Dr. Hao’s academic journey spans over a decade of rigorous training, blending Western scientific research with Traditional Chinese Medicine. He received his bachelor’s degree in clinical medicine and later pursued his Ph.D. in an interdisciplinary program that focused on integrating these two approaches to medicine. His postdoctoral research in vascular pharmacology furthered his expertise in understanding the physiological and molecular mechanisms of cancer-related vascular changes.

Experience:

  • 2014.09-2018.08: Postdoctoral Researcher, Peking Union Medical College, Vascular Pharmacology
  • 2018.08-Present: Assistant Investigator, Peking University Cancer Hospital, Integration of Chinese and Western Medicine

Dr. Hao’s research career spans significant academic institutions in China. During his postdoctoral research at PUMC, he specialized in vascular pharmacology, focusing on the molecular pathways involved in tumor vasculature. At Peking University Cancer Hospital, Dr. Hao continues to investigate how traditional medicine can alter the interactions between cancer cells and endothelial cells, with a goal of developing novel therapeutic strategies for cancer treatment. His interdisciplinary approach has led to multiple breakthrough discoveries in cancer biology and integrative medicine.

Research Focus:

Dr. Hao’s primary research areas include:

  • Investigating the interactions between cancer cells and vascular endothelial cells, and how these affect cancer progression
  • Exploring the role of Traditional Chinese Medicine (TCM) in regulating cancer cell interactions within the tumor microenvironment, especially with endothelial cells

By bridging the gap between modern biomedical science and traditional medicine, Dr. Hao aims to develop therapies that utilize both modalities to inhibit tumor growth and metastasis. His work focuses on understanding how TCM can modulate endothelial cells and vascular pathways, potentially leading to new treatments for cancer that are more holistic and effective.

Publications Top Notes:

  1. Modified Bu-Fei decoction inhibits lung metastasis via suppressing angiopoietin-like 4 🫁🦠
  2. CUEDC2 Drives β-Catenin Nuclear Translocation and Promotes Triple-Negative Breast Cancer Tumorigenesis 🧬💥
  3. Berberine Suppresses Lung Metastasis of Cancer via Inhibiting Endothelial Transforming Growth Factor Beta Receptor 1 🌱🏥
  4. Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF 🌿🧫
  5. The cyclic adenosine monophosphate elevating medicine, forskolin, reduces neointimal formation and atherogenesis in mice 🐭💉
  6. Nitric oxide, a communicator between tumor cells and endothelial cells, mediates the anti-tumor effects of Marsdenia Tenacissima Extract (MTE) 💡🔬
  7. Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity 💊🔬
  8. Marsdenia tenacissima extract dilated small mesenteric arteries via stimulating endothelial nitric oxide synthase and inhibiting calcium influx 🧪🩸
  9. Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE(2) (Prostaglandin E-2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury 💥🩺
  10. Loss of Endothelial CXCR7 Impairs Vascular Homeostasis, and Cardiac Remodeling After Myocardial Infarction ❤️🫀

Conclusion:

Dr. Huifeng Hao’s contributions to cancer research, particularly the intersection of TCM and Western medicine, make him an excellent candidate for the Best Researcher Award. His innovative studies, combined with his dedication to advancing cancer treatment, position him as a leading researcher in his field. His continued research promises to significantly impact both scientific understanding and clinical practices in cancer therapy.